

***THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR
DISSEMINATION IN THE UNITED STATES***

BREATHTEC BIOMEDICAL INC.

Suite 890, 789 West Pender Street
Vancouver, British Columbia, Canada V6C 1H2

Breathtec Biomedical Announces Private Placement

VANCOUVER, BRITISH COLUMBIA – October 18, 2016 – [Breathtec BioMedical, Inc.](http://www.breathtecbiomedical.com) (CSE: BTH) (CSE: BTH.CN) (CNSX: BTH) (the “**Company**” or “**Breathtec**”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases, is pleased to announce that it intends to complete a non-brokered private placement offering of up to 13,333,333 units (the “**Units**”) at a price of \$0.075 per Unit for gross proceeds of up to \$1,000,000 (the “**Offering**”). Each Unit will consist of one common share in the capital of the Company (a “**Share**”) and one transferable common share purchase warrant (a “**Warrant**”), with each Warrant exercisable into one additional Share at a price of \$0.15 for a period of three years from the date of closing.

In connection with the Offering, the Company may pay a finder’s fee on the Offering within the amount permitted by the policies of the Canadian Securities Exchange (the “**Exchange**”).

Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions. The net proceeds from the Offering will be used for general corporate purposes.

For more information, please visit: www.breathtecbiomedical.com.

ON BEHALF OF THE BOARD

"Kal Malhi"
President & Director

For further information, please contact:

Investor Relations
Telephone: +1 (352) 327-3152
Email: investors@breathtecbiomedical.com

The CSE has neither approved nor disapproved the information contained herein.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.